Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-DARPinEc1-G3C is a radiopharmaceutical diagnostic agent consisting of a Designed Ankyrin Repeat Protein (DARPin) named Ec1-G3C labeled with the radioactive isotope technetium-99m (99mTc). It is designed to target the Epithelial Cell Adhesion Molecule (EpCAM), which is frequently overexpressed in various carcinomas, including breast cancer. DARPins are small, stable, engineered proteins that offer high affinity and specificity for their targets, often providing better tissue penetration and faster clearance than full-sized antibodies. This agent is primarily used for SPECT/CT imaging to visualize EpCAM expression in patients with primary triple-negative and luminal breast cancer, facilitating the assessment of tumor distribution and dosimetry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [99mTc]Tc-DARPinEc1-G3C.